Last checked at 3 Dec 2021 11:07
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Publication of Annual Report and Accounts and Notice of Annual General Meeting
York, U.K. 3 December 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, is pleased to announce is pleased to announce that its Annual General Meeting ('AGM') will be held on Friday 24 December at 9.30 a.m. at the offices of Abingdon Health, York Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom.
Given the continued uncertainty relating to COVID-19, shareholders are encouraged to vote by proxy in advance of the AGM or appointing the chair of the meeting as their proxy.
The Company's Annual Report and Accounts for the year ended 30 June 2021 together with the notice convening the AGM and related form of proxy has been sent to shareholders and is available on the Company's website www.abingdonhealth.com.
Enquiries:
Abingdon Health plc | www.abingdonhealth.com/investors/ | ||
Chris Yates, Chief Executive Officer | Via Walbrook PR | ||
Melanie Ross, Chief Financial Officer | |||
Christopher Hand, Non-Executive Chairman | |||
Singer Capital Markets (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 7496 3000 | ||
Shaun Dobson, Peter Steel, Alex Bond (Corporate Finance) | |||
Tom Salvesen (Corporate Broking) | |||
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | ||
Paul McManus / Phillip Marriage | Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082 | ||
Alice Woodings | Mob: +44 (0)7407 804 654 | ||
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com